Avalo Therapeutics (NASDAQ:AVTX) Coverage Initiated by Analysts at Wolfe Research

Key Points

• Wolfe Research initiated coverage with an Outperform rating and a $48 price target (implying ~233% upside); analysts' consensus is a "Moderate Buy" with an average target of about $44.83.
• Avalo is a clinical-stage biotech (lead programs AVTX‑002 and AVTX‑006) with a market cap around $328 million, the stock trading near $14.41 (52‑week range $3.39–$20.72), and it reported an EPS of ($0.37) for the quarter, beating expectations.
• Insiders have sold about 46,100 shares (~$765k) in the last 90 days (including Rule 10b5‑1 trades), while institutional investors hold roughly 87% of the company.

Analysts at Wolfe Research assumed coverage on shares of Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) in a research report issued on Thursday. The brokerage set an "outperform" rating and a $48.00 price target on the stock. Wolfe Research's price objective indicates a potential upside of 233.10% from the company's previous close.

A number of other equities research analysts also recently weighed in on AVTX. Mizuho upgraded shares of Avalo Therapeutics to a "strong-buy" rating in a research report on Thursday, December 18th. Weiss Ratings reissued a "sell (d-)" rating on shares of Avalo Therapeutics in a research report on Friday, January 9th. Citizens Jmp started coverage on Avalo Therapeutics in a report on Monday. They issued an "outperform" rating and a $52.00 price objective for the company. BTIG Research reiterated a "buy" rating and set a $40.00 target price on shares of Avalo Therapeutics in a research report on Tuesday, March 24th. Finally, HC Wainwright increased their target price on Avalo Therapeutics from $25.00 to $40.00 and gave the stock a "buy" rating in a report on Wednesday, March 25th. One analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat, Avalo Therapeutics has a consensus rating of "Moderate Buy" and an average target price of $44.83.

Avalo Therapeutics Stock Performance

AVTX stock opened at $14.41 on Thursday. Avalo Therapeutics has a 52 week low of $3.39 and a 52 week high of $20.72. The company has a market capitalization of $328.40 million, a PE ratio of -2.51 and a beta of 0.93. The company's 50-day simple moving average is $15.54 and its 200 day simple moving average is $16.09.

Avalo Therapeutics (NASDAQ:AVTX - Get Free Report) last issued its quarterly earnings data on Monday, March 23rd. The company reported ($0.37) earnings per share for the quarter, topping the consensus estimate of ($1.54) by $1.17. The business had revenue of $0.06 million during the quarter, compared to analyst estimates of ($0.21) million. On average, analysts forecast that Avalo Therapeutics will post -19.07 EPS for the current year.

Insider Buying and Selling

In related news, insider Mittie Doyle sold 3,970 shares of the stock in a transaction that occurred on Monday, April 6th. The shares were sold at an average price of $18.01, for a total transaction of $71,499.70. Following the sale, the insider owned 3,622 shares in the company, valued at approximately $65,232.22. This trade represents a 52.29% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Christopher Ryan Sullivan sold 7,980 shares of Avalo Therapeutics stock in a transaction that occurred on Thursday, April 2nd. The shares were sold at an average price of $17.15, for a total transaction of $136,857.00. Following the completion of the transaction, the chief financial officer directly owned 17,338 shares in the company, valued at $297,346.70. This trade represents a 31.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last ninety days, insiders have sold 46,100 shares of company stock valued at $764,724. 3.03% of the stock is currently owned by insiders.

Institutional Trading of Avalo Therapeutics

Large investors have recently bought and sold shares of the business. Geode Capital Management LLC grew its position in Avalo Therapeutics by 2.5% in the second quarter. Geode Capital Management LLC now owns 110,460 shares of the company's stock valued at $552,000 after acquiring an additional 2,648 shares during the last quarter. Nantahala Capital Management LLC boosted its stake in shares of Avalo Therapeutics by 10.6% in the 2nd quarter. Nantahala Capital Management LLC now owns 995,000 shares of the company's stock valued at $4,965,000 after purchasing an additional 95,000 shares in the last quarter. Bank of America Corp DE grew its holdings in shares of Avalo Therapeutics by 7,066.8% during the 2nd quarter. Bank of America Corp DE now owns 406,571 shares of the company's stock valued at $2,029,000 after purchasing an additional 400,898 shares during the last quarter. Boothbay Fund Management LLC bought a new stake in shares of Avalo Therapeutics during the 2nd quarter valued at approximately $56,000. Finally, Aberdeen Group plc acquired a new position in Avalo Therapeutics during the 3rd quarter worth approximately $925,000. 87.06% of the stock is owned by institutional investors and hedge funds.

Avalo Therapeutics Company Profile

Avalo Therapeutics is a clinical-stage biotechnology company focused on the discovery, development and commercialization of novel therapies for cardiometabolic, fibrotic and inflammatory diseases. The company's proprietary drug-design platform enables the creation of long-acting prodrugs with optimized pharmacokinetic profiles, aiming to improve efficacy, safety and patient adherence. By leveraging this technology, Avalo seeks to address key drivers of disease progression that remain underserved by existing treatments.

Its lead programs include AVTX-002, a first-in-class prodrug candidate designed to inhibit angiotensinogen for the treatment of hypertension and related cardiovascular disorders, and AVTX-006, an early-stage candidate targeting pathways implicated in fibrosis and metabolic dysfunction.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.